Darolutamide (Nubeqa®) in nonmetastatic, castration-resistant prostate cancer (nmCRPC). Update July 2020

Grössmann, N. (2020): Darolutamide (Nubeqa®) in nonmetastatic, castration-resistant prostate cancer (nmCRPC). Update July 2020. Oncology Fact Sheet Nr. 2.

[thumbnail of Oncology Fact Sheet Nr.2_Update.pdf]

Preview

PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader
78kB

Item Type:	Oncology Fact Sheet
Subjects:	WB Practice of medicine > WB 300-962 Therapeutics WJ Urogenital system > WJ 700-875 Male genitalia QZ Pathology > QZ 200-380 Neoplasms.Cysts QV Pharmacology, toxicology, pharmacy > QV 60-370 Pharmacology
Language:	English
Series Name:	Oncology Fact Sheet Nr. 2
Deposited on:	29 Mar 2020 02:22
Last Modified:	31 Jul 2020 09:46

Repository Staff Only: item control page